Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 979
countries
28
conditions
2 106

55 trials match your criteria

Breast cancer

Recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

HER2 positive endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Breast cancer+3

Recruiting

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

HER2 positive breast cancer

Recruiting

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab

Triple negative breast cancer

Recruiting

Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan

Breast cancer metastatic

Recruiting

Study of Trastuzumab Deruxtecan Blood Levels in Normal Weight and Overweight Patients with Metastatic Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Colorectal cancer metastatic

Recruiting

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Oesophageal adenocarcinoma

Recruiting

Study of rilvegostomig, trastuzumab deruxtecan, and AZD0901 in patients with locally advanced resectable gastroesophageal cancer before and after surgery

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901

Endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

HER2 positive gastric cancer

Recruiting

Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.